Introduction
============

Uveitis, an ophthalmological illness, has environmental and polygenic influences that bring about loss of vision and implicates many heterogeneous diseases, all characterized by intraocular inflammation, which commences in the uvea, and whose otherwise involved immune pathways have been precisely described ([@B75]). Several causes are involved, e.g., infections and systemic autoimmune disorders.

Ocular inflammation involves mainly the uveal tract, but it can be extended to additional ocular structures, such as the vitreous or retina. The main invading immune cells are T-lymphocytes and monocyte-derived macrophages, which are located in growing lesions ([@B43]). Both of these cell types release an array of soluble inflammatory mediators (chemokines and cytokines), which are vital for disease onset and disease progress ([@B71]). Some cytokines are protective or inflammatory, which depends on the time they take place. Apart from this complex paradigm, many other cytokines also have antithetical effects depending on the context in which they are released ([@B11]).

Endotoxin-induced uveitis (EIU) is an acute uveitis procedure that can be caused by systemically injecting into rats a sublethal lipopolysaccharide (LPS) dose, a constituent of Gram-negative bacteria's cell walls. Hence, it has not only been seen as a valuable model of human anterior uveitis and panuveitis ([@B61]; [@B34]), which is not autoimmune, but is also a useful model for procedures of acute ocular inflammatory driven by innate immune ways ([@B7]). The application to humans of the results obtained in the EIU model is considered useful to study a part of the endogenous uveitis (the faculty of some bacteria and toxins to act on uveal tissues has been known since ancient times), some of which have been related to infections by gram negative bacteria ([@B48]). EIU is characterized by iris vasodilatation and vascular alterations in the ciliary body, complemented by augmented vascular permeability and blood--aqueous barrier breakdown ([@B9]; [@B23]). In the eye's anterior segment, an alteration of the blood barrier involves protein leakage into the anterior chamber and subsequent macrophage and neutrophil infiltration. Inflammation appears 4 h after injecting LPS, peaks after 24--48 h, and decays 96 h after inducing the disease ([@B61]; [@B75]; [@B9]). There is plenty of experimental and clinical evidence that support the role of specific Gram-negative bacteria, or their LPS, in the pathogenesis of non-infectious immune-mediated uveitis ([@B9]).

Endotoxin-induced uveitis model mimics the pathologies in human acute uveitis ([@B61]; [@B34]). Therefore, in the EIU model, chemokines and cytokines are also important in the response. Thus, during animal model progress and modulation for not only panuveitis, but also for acute ocular inflammation ([@B61]), several chemokines and cytokines released by infiltrating cells, e.g., INFγ (interferon gamma), IL-1 (interleukin-1), TNFα (tumor necrosis factor alpha), IL-6 (interleukin-6), MCP-1 (monocyte chemoattractant protein-1), RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted) and other inflammatory mediators, play an essential role ([@B75]; [@B23]; [@B73]). Type 1 T helper cells (Th1) activation in EIU appears predominant, but takes place with any kind of Type 2 T helper cells (Th2) contribution ([@B75]). Thus, not only the release of cytokines/chemokines, but also LPS activation of mononuclear and neutrophil cells in eye tissues, induce the secretion of different substances, such as free radicals and proteolytic enzymes, which have been associated with oxidative stress ([@B82]; [@B64]).

Bevacizumab is a full-length monoclonal antibody (149 kDa) that was designed and considered mainly to be an anti-angiogenic approach to treat a wide range of solid tumors ([@B14]). After its approval by the US Food and Drug Administration (FDA), ophthalmologists administered Bevacizumab to treat a variety of neovascular diseases. In experimental models, vascular endothelial grow factor (VEGF) inhibition of choroidal neovascularization and diabetic retinopathy have obtained auspicious results ([@B62]; [@B52]). Bevacizumab use is now widespread to treat any ocular disease that implies neovascularization. Promising results have been obtained from intravitreal injections of anti-VEGF agents in other ocular diseases, such as retinopathy of prematurity ([@B51]), neovascular glaucoma ([@B15]), macular edema of diabetic patients ([@B77]) and intraocular tumors ([@B13]). Bevacizumab has been employed to treat and stabilize subsequent uveitis complications, e.g., uveitis macular edema ([@B37]), choroidal neovascularization ([@B19]), and retinal vasculitis ([@B47]). Nevertheless, its use in primary defeat inflammation has never been established. And it has never been mechanistically assessed in an animal model. [@B56] have recently evaluated if intravitreal Bevacizumab was safe as monotherapy in various eye diseases and reported low rates of severe adverse effects after intravitreal Bevacizumab treatment in comparison to other intravitreal therapies. However, in clinical practice undesired events and usual complications can occur when injecting intravitreal anti-VEGF agents, and they can be potentially severe ([@B16]) such as endophthalmitis ([@B40]), intraocular inflammation ([@B74]), ocular hemorrhaging ([@B49]), etc. Accordingly, we previously demonstrated that an intravitreal Bevacizumab injection *per se* generates transient and mild, yet immediate inflammation in rat eyes, which has not been related to oxidative stress in ocular tissues ([@B63]). Such injections have also resulted in a several-fold increase in RANTES, MCP-1, and INFγ concentrations in the aqueous humors of rats treated with endotoxin ([@B26]).

Our research was focused on the study of the possible effect and, for the first time, the mechanism of Bevacizumab. Bevacizumab is a monoclonal antibody that includes human framework regions, ∼93% human and 7% murine protein sequence, and the complementarity-determining regions of a murine antibody which binds to VEGF ([@B59]; [@B69]). After several years questioning Bevacizumab-murine VEGF interaction ([@B33]; [@B38]; [@B4]; [@B22]; [@B10]; [@B32]; [@B80]; [@B70]) and its use in murine animal models, many recent works have confirmed its use in rats ([@B30]; [@B36]). Indeed, recent experiments showed the affinity of fluorescent-labeled bevacizumab to recombinant rat VEGF~164~, but with a comparable lower affinity to the rat protein than to recombinant human VEGF ([@B46]). The binding profile of Bevacizumab to human, mouse, and rat VEGF-A is similar when tested by direct enzyme-linked immunosorbent assay (ELISA) ([@B25]). Bevacizumab interacts with human VEGF-A at 21 residues ([@B50]). There is a single amino acid substitution in rat VEGF-A ([@B25]). This minor change at the binding site might elucidate why bevacizumab binding to rat VEGF-A is weaker. In fact, binding to rat VEGF-A is similar to human VEGF-A at five orders of magnitude higher antibody concentration ([@B25]).

Materials and Methods {#s1}
=====================

Animals
-------

Male Lewis rats, weighing 250--300 g, aging 10 weeks (Harlan Ibérica SL, Barcelona, Spain) were used in accordance with international EU (86/608/EEC), ARVO (Association for Research in Vision and Ophthalmology) and ARRIVE (Animal Research: Reporting of In Vivo Experiments) ([@B27]; [@B41]) regulations on handling animals. The study was approved by the Ethics Committee of Animal Experiments at the Universidad CEU-Cardenal Herrera (Permit No. 315/2006). Animals were confined individually and remained in a 12 h/12 h light/dark cycle, with regulated temperature (20°C) and relative humidity (60%) and *ad libitum* access to food and water. Rats were anesthetized by intraperitoneally (i.p.) injection of ketamine (100 mg/kg body weight) and azepromazine (2.5 mg kg^-1^ body weight). Animals were divided randomly into five experimental groups. A drop of topical anesthetic (procaine + oxybuprocaine) was administered three times every 3 min previous to the intravitreal injection. In addition, one drop of antibiotic (Polymyxin B Sulfate, gramicidin, and neomycin sulfate) was administered before intravitreal injection and every 8 h afterward.

Endotoxin-induced uveitis (the E group, *n* = 14) was provoked by footpad injections of 200 μg LPS (100 μg per footpad) from *Salmonella typhimurium* (Sigma-Aldrich, St. Louis, MO, United States), diluted in 0.2 mL saline solution. The saline solution control animals received the same volume of saline solution that was given with LPS (the S group, *n* = 10). The biological effect of Bevacizumab in rat models has been attributed to the fact that binding to rat VEGF-A is similar to human VEGF-A at five orders of magnitude higher antibody concentration ([@B46]). Vitreous volume in adult rat eye is about 50 μL ([@B67]) and about 4 mL in human eye ([@B1]). Typical Bevacizumab human dose is 1.00--1.25 mg in adults. Therefore, 80 μg of Bevacizumab (Avastin, Genentech, United States) was the chosen dose, a dose which in vitreous humor rat eye is 5.1--6.4 orders of magnitude higher concentration than human typical dose. Immediately after LPS footpad injection, one group of rats was slowly injected intravitreally (i.v.) with Bevacizumab (group E+B, *n* = 12; 80 μg in 3 μL samples) diluted in saline solution. A second group of rats not injected with the previous LPS footpad was also administered with Bevacizumab (80 μg in 3 μL samples; group B, *n* = 10). Similarly, E group was injected with an intravitreal saline solution and a fourth group (S group) was injected with the same saline solution. Finally, a fifth group (C group, *n* = 10) did not receive any treatment. The treatments and quantity of rats used are shown in **Table [1](#T1){ref-type="table"}**. Animals were monitored every 8 h until sacrifice.

###### 

Summary of the treatment groups.

  Footpad injection   Intravitreal injection   Treatment group               No. of animals
  ------------------- ------------------------ ----------------------------- ----------------
  None                None                     Control (C)                   10
  Saline              Saline                   Saline (S)                    10
  Saline              Bevacizumab              Bevacizumab (B)               10
  Endotoxin           Saline                   Endotoxin (E)                 14
  Endotoxin           Bevacizumab              Endotoxin+Bevacizumab (E+B)   12

Animals were anesthetized with sodium pentobarbital injected intraperitoneally and sacrificed by cervical dislocation 24 h after Bevacizumab and/or LPS treatment. The aqueous humor was taken out and enucleation was carried out immediately. Eyes were collected in 10% buffered paraformaldehyde for histopathological evaluations or frozen at -80°C until being processed for biochemical analyses.

Aqueous Humor Collection and Cell Counting
------------------------------------------

Immediately after sacrificing animals, aqueous humors were collected from both eyes by anterior chamber puncture with an insulin syringe, and around 20 μL per rat were obtained. Blood--aqueous barrier integrity was evaluated 24 h after inducing uveitis by assessing two parameters in aqueous humors: cell count and protein concentration. For cell count, an aqueous humor aliquot was diluted in an equal volume of trypan blue. Cells were counted by a hemocytometer under light microscopy. The number of viable/non-viable cells (the equivalent to 0.1 μL) was counted manually per field, whereas the number of cells per microliter was obtained by averaging the results of at least four fields from each sample. Having completed cell counts, aqueous humors were centrifuged for 5 min at 300 *g*. The cell-free supernatant was removed and frozen at -80°C until being used.

Histopathological Evaluation
----------------------------

Eyes remained in buffered paraformaldehyde for 24--48 h and then they were paraffin-embedded in accordance with standard procedures. Sagittal sections (3-μm thick) were cut close to the optic nerve head, and He-stained (hematoxylin and eosin). The histopathology of all the ocular structures (cornea, lens, uvea, retina, choroid, sclera and anterior, posterior, and vitreous chambers) was studied, identifying extravasated inflammatory cells such as neutrophils and monocytes/macrophages. Two independent observers scored the histopathological inflammation signs using grades 0--3: no infiltrating cells "0," mild "1," moderate "2," or severe "3" cell infiltration.

Biochemical Analysis
--------------------

Eyes were enucleated and lenses removed after assuming their elevated glutathione concentration. Lensless eyes were frozen at -80°C until treated for the biochemical analysis of oxidative stress markers: glutathione (GSH), malondialdehyde (MDA) concentrations, and glutathione peroxidase (GSH-Px) activity. Lensless eyes were homogenized in 0.2 M potassium buffer, pH 7.0 and were frozen at -20°C until used.

Protein concentration was quantified following the method of [@B35] with modifications ([@B55]). The aqueous humor samples were submitted to ELISAs in order to measure the levels of diverse chemokine proteins (GRO/KC, MIP-2, and MIP-3α) and cytokine proteins (IL-1β, IL-2, IL-6, IL-10, TNFα, and INFγ). ELISAs (Searchlight Multiplex rat Assays; Pierce Biotechnology, Inc., Woburn, MS, United States) were performed according to the manufacturer's guidelines.

Malondialdehyde was measured in eye homogenates by HPLC (Waters-LC Module I Plus, Waters Cromatografia SA, Spain) following Richard's procedure ([@B58]) modified by [@B60]. HPLC was run in a Spheryc-5, ODS 5 μm, 250 mm × 4.6 mm column (Brownlee-Columns) at a 1 mL/min flow rate. Values were expressed as nmol/mg of protein.

Glutathione was similarly measured in eye homogenates by HPLC (Gilson International B.V. Spain) in accordance with the procedure of [@B57]. A 3-Spherisorb NH~2~ 5 μm, 250 mm × 4.6 mm column (Waters Cromatografia, SA, Spain) was used at a 1 mL/min flow rate. Values are expressed as nmol/mg of protein.

Glutathione peroxidase activity was evaluated spectrophotometrically by monitoring NADPH oxidation at 340 nm, in line with [@B31]. Values are expressed as nmol/min of NADPH oxidized per mg of protein.

Statistical Analysis
--------------------

Data are expressed as mean ± SE. Inter group comparisons were made by one-way analysis of variance (ANOVA) and false discovery rate-adjusted *P*-value \[FDR\] \< 0.05. The ANOVA of the data acquired by the Brown-Forsythe test was run by the Tukey test as a *post hoc* test when variances of data were homogeneous (*p* \< 0.05), or by a Dunnett T3 test when variances differed. Statistical differences were set at *p* ≤ 0.05. Statistical tests were carried out using GraphPad Prism version 7.04 for Windows (GraphPad Software, La Jolla, CA, United States) and SPSS statistical software package v24 (IBM, Corp. Released 2016. IBM SPSS Statistics for Windows, Version 24.0., Armonk, NY, United States: IBM, Corp.).

Results
=======

Effect of Bevacizumab on Protein and Cellular Concentration in Aqueous Humors
-----------------------------------------------------------------------------

Intense inflammation was observed in the rat anterior chamber of eyes 24 h after administering endotoxin, which indicates disrupted blood--barrier integrity. Hence, the inflammatory cellular content (*p* ≤ 0.05 vs. C and S groups; **Figure [1A](#F1){ref-type="fig"}**) and protein concentration (*p* ≤ 0.05 vs. C and S groups; **Figure [1B](#F1){ref-type="fig"}**) in the aqueous humors of the endotoxin-treated rats significantly increased. Moreover, statistically significant differences were observed in the inflammatory cellular content in aqueous humors between the data from the control group and the Bevacizumab groups (*p* ≤ 0.05 vs. C group; **Figure [1A](#F1){ref-type="fig"}**). A non-significant increasing tendency in the aqueous humor protein concentration tended to significantly increase in the Bevacizumab group (*p* \> 0.05 vs. C and S groups; **Figure [1B](#F1){ref-type="fig"}**). Nevertheless, administering Bevacizumab with endotoxin moderately reduced the inflammation noted in the anterior chamber of eyes since a significant drop in cellular content was noted (*p* ≤ 0.05 vs. E group; **Figure [1A](#F1){ref-type="fig"}**), which was not found in the aqueous humor protein concentration (*p* \> 0.05 vs. E group; **Figure [1B](#F1){ref-type="fig"}**).

![Effect of endotoxin and/or Bevacizumab on cellular content **(A)** and protein concentration **(B)** in the aqueous humors collected 24 h following treatment, and on the histopathological score of anterior chamber **(C)**, posterior chamber **(D)**, ciliary body **(E)**, vitreous chamber **(F)**, and retina **(G)** cellular infiltration. Each value is shown as mean ± SE. ^∗^*p* ≤ 0.05 vs. the Control group, ^+^*p* ≤ 0.05 vs. the Saline group and ^\#^*p* ≤ 0.05 vs. the Endotoxin group.](fphar-09-00649-g001){#F1}

Histopathological Findings
--------------------------

Panuveitis was reached by endotoxin treatment and verified by the significant increase in the quantity of inflammatory cells in all the intraocular tissues studied (*p* ≤ 0.05 vs. C and S groups; **Figures [1C](#F1){ref-type="fig"}--[G](#F1){ref-type="fig"}, [2C,S](#F2){ref-type="fig"}**) in histopathological sections (**Figures [2E1--E4](#F2){ref-type="fig"}**). The simultaneous administration of Bevacizumab mainly prevented endotoxin-induced uveitis (EIU) and a significant decrease was observed in the histopathological gradings of the anterior and posterior chambers (**Figures [1C,D](#F1){ref-type="fig"}**, *p* ≤ 0.05 vs. E group; **Figures [2E+B1,E+B2](#F2){ref-type="fig"}**). As mentioned above, endotoxin treatment led to a significant increase in the inflammatory cells in the ciliary body (*p* ≤ 0.05 vs. C and S groups, **Figures [1E](#F1){ref-type="fig"}, [2E1,E2](#F2){ref-type="fig"}**) and was more serious than in the anterior and posterior chambers (*p* ≤ 0.05 vs. C and S groups, **Figures [1C,D](#F1){ref-type="fig"}, [2E1,E2](#F2){ref-type="fig"}**). No significant decreasing tendency in endotoxin-induced ciliary body inflammation was noted when Bevacizumab was administered simultaneously (*p* \> 0.05 vs. E group, **Figures [1E](#F1){ref-type="fig"}, [2E+B1,E+B2](#F2){ref-type="fig"}**). The number of inflammatory cells in the retina and vitreous chamber significantly grew after LPS treatment (*p* ≤ 0.05 vs. C and S groups, **Figures [1F,G](#F1){ref-type="fig"}, [2E3,E4](#F2){ref-type="fig"}**) and were found all over retinal layers. Administering Bevacizumab with endotoxin largely prevented inflammation in the retina and vitreous chamber (*p* ≤ 0.05 vs. E group, **Figures [1F,G](#F1){ref-type="fig"}, [2E+B3,E+B4](#F2){ref-type="fig"}**) and inflammatory cells were observed only in the innermost retinal layer (**Figure [2E+B4](#F2){ref-type="fig"}**). Interestingly, the inflammatory cell score in many intraocular structures sharply rose in the Bevacizumab group, which included the anterior and posterior chambers (*p* \< 0.05 vs. C and S groups; **Figures [1C,D](#F1){ref-type="fig"}, [2B1,B2](#F2){ref-type="fig"}**), the ciliary body (*p* \< 0.05 vs. C and S groups; **Figures [1E](#F1){ref-type="fig"}, [2B1,B2](#F2){ref-type="fig"}**) and the vitreous chamber (*p* \< 0.05 vs. C group; **Figures [1F](#F1){ref-type="fig"}, [2B3](#F2){ref-type="fig"}**) but not the retina. The infiltration cell score for the retina was similar to that of the control and saline solution groups (**Figures [1G](#F1){ref-type="fig"}, [2B4](#F2){ref-type="fig"}**). Inflammatory cells did not appear in infiltrate lenses or the cornea in any study group.

![Histopathological study of ocular structures 24 h after Bevacizumab and/or endotoxin treatment, stained with HE. Picture number 1: Ciliary body, anterior and posterior chambers, 20x. Picture number 2: Inset of picture number 1, 63x. Picture number 3: Vitreous chamber, 63x. Picture number 4: Retina, 63x. Inflammatory cells were not observed in either the Control **(C)** or the Saline **(S)** group. Inflammatory cells were seen to infiltrate extravascular uveal tissue in Bevacizumab-treated eyes **(B)**, and reached all the studied structures, apart from the retina (ciliary body, anterior, posterior, and vitreous chambers). Many inflammatory cells neutrophils (black arrow) and monocytes/macrophages (white arrow), were found to infiltrate extravascular uveal tissue in the endotoxin-treated eyes **(E)** and reached all the structures under study (ciliary body, anterior, posterior and vitreous chambers, and retina). A significant reduction was noted when Bevacizumab was also injected (**E+B**, ciliary body, anterior, posterior and vitreous chambers, and retina).](fphar-09-00649-g002){#F2}

Bevacizumab Hinders Endotoxin-Induced Oxidative Stress
------------------------------------------------------

Diverse oxidative stress parameters were measured in rat eye homogenates 24 h after Bevacizumab and/or endotoxin treatment. Endotoxin significantly reduced GSH-Px activity and GSH levels (*p* ≤ 0.05 vs. C, S, and B groups; **Figures [3A,B](#F3){ref-type="fig"}**) which were completely recovered after simultaneous Bevacizumab administration (*p* ≤ 0.05 vs. E group, and *p* \> 0.05 vs. C, S, and B groups). Likewise, endotoxin brought about a twofold significant increase in lipid peroxidation (*p* ≤ 0.05 vs. C, S, and B groups; **Figure [3C](#F3){ref-type="fig"}**), while simultaneous Bevacizumab administration inhibited lipid peroxidation because MDA concentrations reverted to control values (*p* ≤ 0.05 vs. E group, and *p* \> 0.05 vs. C, S, and B groups).

![Effect of Bevacizumab on endotoxin-induced oxidative stress in rat eyes. Glutathione peroxidase activity **(A)**, glutathione **(B)**, and malondialdehyde **(C)** concentrations were measured in the eye homogenates of all the study groups. Each value is shown as mean ± SE. ^∗^*p* ≤ 0.05 vs. the Control and Saline groups, and ^\#^*p* ≤ 0.05 vs. the Endotoxin group.](fphar-09-00649-g003){#F3}

Bevacizumab Affects Chemokines and Cytokines in EIU
---------------------------------------------------

Bevacizumab caused the protective IL-6 and IL-10 cytokines values and some macrophage-related chemokine values to rise after LPS treatment (**Figures [4C,D](#F4){ref-type="fig"}**). Systemic endotoxin injection significantly increased the aqueous humor levels of a wide range of inflammatory mediators, including all the measured cytokines (*p* ≤ 0.05 vs. C and S groups; **Figure [4](#F4){ref-type="fig"}**) and the control values increased between 30 and 100-fold. Simultaneous Bevacizumab and endotoxin administration led to a significant variation in IL-2 cytokine which, compared to the control values, increased 76-fold after administering endotoxin (**Figure [4B](#F4){ref-type="fig"}**) but decreased significantly when Bevacizumab and endotoxin were administered together (*p* ≤ 0.05 vs. E Group). Some monocyte-related cytokines (IL-6 and TNFα) increased when Bevacizumab was administered with endotoxin (**Figures [4C,E](#F4){ref-type="fig"}**). Cytokine IL-6 also rose considerably (*p* ≤ 0.05 vs. E Group; **Figure [4C](#F4){ref-type="fig"}**) under these conditions. IL-10 significantly increased after administering Bevacizumab and endotoxin together (*p* ≤ 0.05 vs. E Group; **Figure [4D](#F4){ref-type="fig"}**). Likewise, for cytokines, the LPS treatment led to significant increases in the concentration of all the chemokines measured in aqueous humor (*p* ≤ 0.05 vs. C, S, and B groups; **Figure [5](#F5){ref-type="fig"}**) and the control values rose between 12 and 500-fold. The effect that Bevacizumab had on endotoxin-stimulated chemokines was heterogeneous and caused no significant variations in MIP-3α compared to the E group (*p* \> 0.05 vs. E Group; **Figure [5B](#F5){ref-type="fig"}**), while significant increases (*p* ≤ 0.05 vs. E Group; **Figures [5A,C](#F5){ref-type="fig"}**) were observed in two related macrophage chemokines: MIP-2 and GRO/KC.

![Effects of Bevacizumab on cytokine concentration (pg/mL) in the aqueous humors of all the study groups. IL-1b **(A)**, IL-2 **(B)**, IL-6 **(C)**, IL-10 **(D)**, TNFα **(E)**, and INFγ **(F)** concentrations were measured. Each value is shown as mean ± SE. ^∗^*p* ≤ 0.05 vs. the Control group, *ˆp* ≤ 0.05 vs. the Saline group, ^+^*p* ≤ 0.05 vs. the Bevacizumab group and ^\#^*p* ≤ 0.05 vs. the Endotoxin group.](fphar-09-00649-g004){#F4}

![Effects of Bevacizumab on chemokine concentration (pg/mL) in the aqueous humors of all the study groups. MIP-2 **(A)**, MIP-3a **(B)**, and GRO/KC **(C)** concentrations were measured. Each value is shown as mean ± SE. ^∗^*p* ≤ 0.05 vs. the Control, Saline solution and Bevacizumab groups, and ^\#^*p* ≤ 0.05 vs. the Endotoxin group.](fphar-09-00649-g005){#F5}

Discussion
==========

Our results show the effects of Bevacizumab, a humanized anti-VEGF agent, in an animal model of non-autoimmune acute ocular inflammation. We found that Bevacizumab prevented endotoxin-induced inflammation in the anterior chamber of the eye because cellular content was reduced significantly and lowered histopathological grade obtained in anterior and posterior chambers (**Figures [1A](#F1){ref-type="fig"}--[E](#F1){ref-type="fig"}, [2E+B1,E+B2](#F2){ref-type="fig"}**). Bevacizumab also prevented inflammation in the retina and vitreous chamber (**Figures [1F,G](#F1){ref-type="fig"}, [2E+B3,E+B4](#F2){ref-type="fig"}**). Bevacizumab inhibits VEGF from binding to its receptors (Flt-1 and KDR) on the endothelial cell surface and, as a result, neutralizes the biologic activity of VEGF. Thus, the significant reduction observed in both cell infiltration and histopathological grading of distinct ocular structures might be associated directly with this primary mechanism of action of Bevacizumab. VEGF displays vascular permeability via numerous mechanisms, including junctional remodeling, induction of fenestrae, and vesiculo-vacuolar organelles. Hence, VEGF like other inflammatory mediators (bradykinin, thrombin, histamine, etc.), disrupt the organization of integrin-extracellular matrix complexes and inter-endothelial junctions which open the junctional barrier. VEGF simultaneously activates several signaling pathways implicated in vascular permeability, including phospholipase C-dependent intracellular calcium release, eNOS signaling, cytoskeletal rearrangement, src kinase-mediated phosphorylation/internalization of junctional proteins and RhoGTPase activation. Therefore, minute intercellular gaps which are formed are allowing an unrestricted passage of plasma proteins, including liquid and albumin, to cross the endothelial barrier ([@B18]; [@B42]). Recently, a study ([@B8]) has associated treatment with Bevacizumab in age-related macular degeneration with IL-6 cytokine, and suggested that IL-6 could be a major marker of treatment response and resistance.

In the group treated only with Bevacizumab, it was noteworthy that the cellular content significantly increased in aqueous humor (**Figures [1A](#F1){ref-type="fig"}, [2B1--B3](#F2){ref-type="fig"}**). This phenomenon was noted in all the ocular structures that we studied (**Figures [1C](#F1){ref-type="fig"}--[F](#F1){ref-type="fig"}, [2B1--B3](#F2){ref-type="fig"}**), except for the retina (**Figures [1G](#F1){ref-type="fig"}, [2B4](#F2){ref-type="fig"}**). In fact, the infiltration cell score obtained for the retina after administering Bevacizumab was similar to those for the saline solution and control groups. Other studies have similarly reported undesirable effects when higher intravitreal Bevacizumab doses were used, which resulted in ultrastructural alterations, transitory inflammation, and apoptosis in rabbit eyes ([@B39]; [@B2]). Our group has previously indicated that this effect disappeared within 1 week ([@B26]). Angiogenesis is a necessary step to achieve wound healing. Some agents that impair blood vessel growth, e.g., Bevacizumab, could be expected to interfere with wound repair after an intravitreal injection. Following corneal epithelial injury in rabbits and rats, Bevacizumab can delay corneal epithelial wound healing, probably via the inhibited nerve growth factor expression ([@B29], [@B28]).

All in all, and despite an early increase in inflammation, the fact that administering Bevacizumab (Bevacizumab group) did not alter retina histopathological grading is a very interesting finding. Bevacizumab with endotoxin (Endotoxin + Bevacizumab group) administration greatly prevented the inflammation observed in the retina at 24 h post-treatment (**Figures [1G](#F1){ref-type="fig"}, [2E+B4](#F2){ref-type="fig"}**). These findings indicate that Bevacizumab is effective treating acute uveitis. In any case, the retina in this acute model would be well-protected from any harmful effect that Bevacizumab could cause. No other animal model study has demonstrated retinal toxicity following intravitreal administration ([@B17]; [@B68]; [@B81]), despite the fact that Bevacizumab possibly interfere with initial postnatal retinal cell differentiation ([@B30]) and with Müller glia activation ([@B21]).

We also measured relevant oxidative stress-related parameters in rat eye homogenates 24 h after Bevacizumab and endotoxin treatment (**Figure [3](#F3){ref-type="fig"}**). The E+B group showed a sharp rise in intracellular GSH levels vs. the E group. GSH is a usual thiol antioxidant peptide and co-substrate for detoxification enzymes, such as GSH-Px. Concurrently it increased GSH-Px activity, a selenium-containing enzyme which reacts with GSH molecules to control lipid peroxidation. Lipid peroxidation products, like MDA, might inhibit diverse enzymes, e.g., GSH-Px, in a concentration-dependent manner ([@B5], [@B6]). Hence, after Bevacizumab and endotoxin treatment, the high MDA concentration levels noted in the endotoxin-induced rat eyes reverted to the control values. We could attribute this antioxidant defensive outcome of Bevacizumab to some of the Bevacizumab effects observed in this study: first the marked drop in cellular infiltration; second some concomitant changes in the interleukin and chemokine concentrations.

There is abundant data that shows that chemokines and cytokines are relevant in uveitis development because they not only control the nature of immune responses ([@B20]; [@B24]; [@B54]), but also peak 24 h in ocular tissues or fluids in swollen eyes after an LPS injection ([@B72]). Therefore, a high expression of different cytokines like TNFα, INFγ, IL-6, IL-1 and IL-2, has been simultaneously reported with a maximum EIU ([@B12]; [@B79]; [@B44], [@B45]). Th1 activation also appears predominant in the EIU model, but with simultaneous Th2 participation ([@B75]). Our data are consistent with the previous cited studies, such as [@B72] and [@B75], because protein leakage and cellular content reached high levels 24 h after the LPS injection. We also observed various overexpressed chemokines and cytokines in our experimental uveitis model (**Figures [4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}**). It is the case of IL-2, a cytokine that plays pivotal roles in the immune response. IL-2 is critical to the induction of the inflammatory immune response but also to the development and maintenance of T regulatory cells (Tregs). The Th1 lymphocytes-related cytokine IFNγ also rose in the endotoxin-treated animals vs. the control ones. Similarly, cytokines correlated to other inflammatory mediators, e.g., the Th2 lymphocytes ones (IL-10 and IL-6), or the macrophage ones (TNFα, IL-1β, and IL-6,) also showed high levels in this group.

Many of the cytokines that were measured herein showed the beneficial effect of Bevacizumab in EIU. IL-6 and IL-10, two cytokines that have anti-inflammatory properties, increased significantly when Bevacizumab and endotoxin were administered together. Numerous cell types release IL-10, including T- and B-cells (Th2 and Treg cells), monocytes, dendritic cells, macrophages, and mast cells. It seems to mitigate inflammatory responses by lowering the expression of major histocompatibility complex and co-stimulatory molecules upon the antigen presenting cells, and inhibits the release of pro-inflammatory cytokines ([@B76]; [@B65]). Only few studies have revealed that IL-6 is redox-regulated and may preserve organs exposed to oxidative stress. IL-6 may also induce neutrophils apoptosis and, therefore, contribute to neutrophil clearance ([@B66]). When infiltration occurs at the inflammation site, as we can see at **Figures [2B,E,E+B](#F2){ref-type="fig"}** groups, neutrophils generate soluble IL-6 receptor (sIL6R) via proteolytic cleavage of the membrane-bound form (mIL6R). IL-6R proteolytic processing from invading neutrophils could subsequently promote IL-6 trans-signaling in resident tissue cells, which produces a switch from neutrophil recruitment to monocyte recruitment by largely increasing monocyte-attracting chemokines. Furthermore, some authors, such as [@B78], have proposed a role for IL-6 in oxidative stress defense. Nrf2, a redox-sensitive transcription factor, displays cell protection against electrophilic and oxidative stress. Nrf2 is also a great effective activator of antioxidant response element-dependent transcription. [@B78] revealed that Nrf2 is also a potent activator of IL-6 gene transcription *in vivo*.

IL-2 significantly decreased when Bevacizumab was administered with endotoxin. IL-2 is a pleiotropic cytokine that induces T-cell growth, enhances the cytolytic activity of natural killer cells, promotes Tregs differentiation, facilitates activation-induced cell death and inhibits IL-6-dependent signaling events, e.g., down-regulating IL-6 receptor expression ([@B3]). The effect that Bevacizumab had on endotoxin-stimulated chemokines varied. Several related M1 macrophage chemokines (GRO/KC and MIP-2) showed relevant increases (**Figure [5](#F5){ref-type="fig"}**). MIP-2 is a chemokine secreted by macrophages and monocytes that acts as a chemoattractant for polymorphonuclear white blood cells and hematopoietic stem cells. GRO/KC is expressed by epithelial cells, neutrophils, and macrophages. Some authors ([@B53]) have suggested that this chemokine could play any kind of protective role.

This has been the first time that Bevacizumab has been used in non-immune-mediated experimental uveitis with good results. It has been previously employed in humans to treat certain uveitis complications (macular cystic edema or neovascularization), but not as the primary treatment. Our results show the possibility of playing a role in such complex vision-threatening ocular diseases. Nonetheless, more studies are necessary to elucidate subjacent mechanisms of Bevacizumab treatment following vascular leakage in uveitis.
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